HIGHLIGHTS
- who: Hoda Awad et al. from the Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, University of Sharjah have published the paper: Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19, in the Journal: Pharmaceuticals 2022, 15, 1068. of /2022/
- what: The elimination half-life of IVM was reported to be 18-24 h; howIn this review article, the potential use of IVM in the therapy and prophylaxis of ever, its pharmacological antiparasitic activity was reported to be sustained for up to COVID-19 will be discussed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.